Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors

**Background:** Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs). Understanding treatment sequencing and dosing patterns of LA-SSA is essential for clinical decision-making to provide value-based management of NETs. **Objective:** To describe treatment patterns of LA-SSA among patients with NETs and subgroups with carcinoid syndrome (CS) in the United States. **Methods:** This retrospective study utilized claims data from MarketScan® databases to identify patients with NETs and newly treated with LA-SSA between January 1, 2015, and October 31, 2020. Patients were stratified by index LA-SSA (lanreotide and octreotide long-acting release $$LAR$$). Reported 28-day doses were based on claim fields for days’ supply/drug quantity or units of service. Dose escalation was defined as increases in quantity or frequency. Continuous variables, categorical variables, and Kaplan-Meier estimated treatment durations were compared using _t_-tests, chi-square/Fisher’s tests, and log-rank tests, respectively. **Results:** The study included 241 lanreotide and 521 octreotide LAR patients. Compared with octreotide LAR patients, treatment duration was longer for lanreotide patients (median, 41.3 vs 26.8 months; log-rank _p_=.004). Fewer lanreotide patients received rescue treatment with short-acting octreotide (7.9% vs 14.4%; _p_=.011), and a first (6.2% vs 27.3%) and second dose escalation (0.8% vs 5.2%; both _p_<.05). Among patients with doses reported, fewer lanreotide patients received above-label doses (2.5% $$5/202$$ vs 14.4% $$60/416$$; _p_<.001). Among patients who ended treatment during follow-up, fewer lanreotide patients transitioned to another LA-SSA (18.9% $$17/90$$ vs 33.6% $$92/274$$; _p_=.008). Similar treatment patterns were observed in CS subgroups. Results for switched treatment patterns were limited due to insufficient sample sizes. **Discussion:** Real-world treatment patterns of LA-SSA were assessed using more recent administrative claims data. Compared with octreotide LAR patients, lanreotide patients were more likely to remain longer on initial treatment and starting dose without dose escalations and less likely to use rescue treatment and transition to another LA-SSA after discontinuation of the index treatment. **Conclusions:** Findings from this claims study suggest a potential clinical benefit of lanreotide in NET management

Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma

Despite the significant association between obesity and several cancers, it has been difficult to establish an association between obesity and hepatocellular carcinoma (HCC). Patients with HCC often have ascites, making it a challenge to accurately determine body mass index (BMI), and many factors contribute to the development of HCC. We performed a case–control study to investigate whether obesity early in adulthood affects risk, age of onset, or outcomes of patients with HCC

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors

Supervivència lliure de progressió; Tumors neuroendocrinsSupervivencia libre de progresión; Tumores neuroendocrinosProgression-free survival; Neuroendocrine tumorsAccessible prognostic tools are needed to individualize treatment of neuroendocrine tumors (NETs). Data suggest neutrophil/lymphocyte ratios (NLRs) have prognostic value in some solid tumors, including NETs. In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1–2, Ki-67  4; n = 25)]. Furthermore, NLRs were not prognostic in Cox models, irrespective of subgroups used. The therapeutic effect of lanreotide autogel/depot 120 mg was independent of NLRs (P > 0.1). These exploratory post-hoc analyses in patients with advanced intestinal and pancreatic NETs contrast with previous data suggesting NLR has prognostic potential in NETs. This may reflect the inclusion of patients with lower-grade tumors or use of higher NLR cutoff values in the current analysis.The CLARINET study was sponsored by Ipsen, the manufacturer of lanreotide autogel/depot. Medical writing services were provided by Nicky French PhD of Watermeadow Medical (Macclesfield, UK) – an Ashfield Company, part of UDG Healthcare plc – sponsored by Ipsen Ltd, Slough, UK in accordance with Good Publication Practice guidelines